Durham, NC, June 1, 2007 – Thrombotargets Corp., a privately held group of Biotech Companies focused on the discovery and development of innovative drugs, is pleased to announce the appointment of Steve A. Hite as Chief Operating Officer. Reporting to the Executive Vice President, Dr. Luis Caveda, Mr. Hite will be responsible for the development and implementation of business development strategies, and all aspects of corporate management.
Mr. Hite has extensive experience throughout the Far East in sales, marketing and licensed business development over a wide variety of medical and pharmaceutical products and services as well as extensive overseas business assignments.
Mr Hite has successfully managed all aspects of two multinational corporate start-ups in Tokyo, Japan and Princeton, New Jersey. As CEO and COO respectively he effectively managed all aspects of corporate operations for these entities, most recently leading to the completion of an important worldwide product marketing license.
“We are very pleased to have someone of Steve’s talent join Thrombotargets” says Dr. Pedreño, president and Chief Executive Officer. “His extensive experience and skills in the Pacific Rim and US Bio-Pharmaceutical markets will help Thrombotargets to accomplish its business plans including the out license of TT-103MH and the exploitation of BIOPLATFORMSCREEN HTS technologies.”
Upon joining Thrombotargets after his successful tenure at Taiho Pharma USA, Inc., Mr. Hite stated: “I am very impressed with the products and technologies of Thrombotargets, and I am excited to join this company and Work with Javier, Luis and Thrombotargets’ strong management team. Thrombotargets has breakthrough Technologies, first-in-class products and a flexible infrastructure upon which to expand. I look forward to contributing to the continued growth of Thrombotargets.”
Mr Hite holds a BS degree in, Business Management and Marketing. Virtually his entire career he has held executive management positions with multinational companies around the world.
About Thrombotargets Group
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays, Hemosta-BIOPLATFORMSCREEN™, capable to quantify simultaneously clot formation and clot lysis , Oxidant- BIOPLATFORMSCREEN™ to quantify total antioxidant capacity and Athero- BIOPLATFORMSCREEN™, to quantify low-density lipoprotein modification. With these proven proprietary new HTS Platforms (BIOPLATFORMSCREEN™), Thrombotargets group is creating a continuously novel and promising pipeline of drug candidates. TT-103MH, Thrombotargets’ most advanced drug candidate, has recently been granted with an Orphan Drug Designation, and will start Phase I clinical trials in early 2008.
Luis Caveda Ph.D.